MYOS RENS is evaluating the genotypic characteristics and molecular pathways that contribute to the changes seen in muscle and inflammatory disease states associated with sarcopenia and related disorders.
MYOS RENS takes its responsibility to the environment and the community very seriously. MYOS RENS is committed to being a good corporate citizen and welcomes suggestions on enhancing our contributions in this regard.
NSF "Certified for Sport®" Certification Further Demonstrates MYOS' Commitment To Providing Safe, Quality Products
CEDAR KNOLLS, N.J., April 10, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition [...]
Presentation on Tuesday, April 10th at 12:30pm ET in Track 2
CEDAR KNOLLS, N.J., April 3, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a bionutrition company and owner of Fortetropin®, the natural product that helps build lean muscle in conjunction with resistance training, announced that the [...]